124367-33-5

Usage

Uses

Used in Pharmaceutical Synthesis:
1-(3-nitrophenyl)cyclopropane-1-carboxylic acid is used as an intermediate in the pharmaceutical industry for the synthesis of various pharmaceuticals and organic compounds. Its unique cyclopropane ring structure can impart distinctive properties to these compounds, enhancing their efficacy and performance.
Used in Research and Development:
In the field of research and development, 1-(3-nitrophenyl)cyclopropane-1-carboxylic acid is utilized as a versatile compound for exploring new drug design and development strategies. Its cyclopropane ring structure offers potential for creating novel pharmaceutical compounds with improved properties and applications.
Used in Drug Design:
1-(3-nitrophenyl)cyclopropane-1-carboxylic acid is used as a structural component in drug design, where its cyclopropane ring can contribute to the development of innovative pharmaceutical compounds with unique properties and potential therapeutic benefits.
It is crucial to handle 1-(3-nitrophenyl)cyclopropane-1-carboxylic acid with care and caution, as it may possess hazardous properties and should be utilized in a controlled laboratory environment to ensure safety and effectiveness in its applications.

Upstream product

• 106-93-4 ethylene dibromide 
• 180150-74-7 3-nitrophenylacetic acid t-butyl ester 
• 621-50-1 (3-nitrophenyl)acetonitrile 
• 124276-69-3 1-(3-nitrophenyl)cyclopropane-1-carbonitrile 

Relevant academic research and scientific papers

(PYRIDIN-2-YL)AMINE DERIVATIVES AS TGF-BETA R1 (ALK5) INHIBITORS FOR THE TREATMENT OF CANCER

The present invention relates to pharmaceutical compounds, compositions and methods, especially as they are related to compositions and methods for the treatment and/or prevention of a proliferation disorder associated with ΤGFβR1 activity, such as a cancer or fibrosis. The invention provides compounds of Formula (I) and Formula (II) as further described herein having an acidic moiety that enhances tissue specificity for targeted tissues and organs. The invention includes pharmaceutical compositions, pharmaceutical combinations, and methods of use of these compounds for treating conditions including cancer or fibrosis.

Aniline derivatives possessing an inhibitory effect of nitric oxide synthase

Compounds represented by the general formula (1): ? (where R1is SR6or NR7R8, where R6is typically an alkyl group having 1-6 carbon atoms, R7is a hydrogen atom, an alkyl group having 1-6 carbon atoms or a nitro group, and R8is a hydrogen atom or an alkyl group having 1-6 carbon atoms; R2and R3are each typically a hydrogen atom or an alkyl group having 1-6 carbon atoms; R4is a hydrogen atom, an alkyl group having 1-6 carbon atoms or an amidino group of which the amine portion may be substituted by an alkyl or nitro group; R5is a hydrogen atom or an alkyl group having 1-6 carbon atoms; Y1, Y2, Y3and Y4which may be the same or different are each typically a hydrogen atom, a halogen atom or an alkoxy group having 1-6 carbon atoms; n and m are each an integer of 0 or 1), or possible stereoisomers or optically active forms of the compounds or pharmaceutically acceptable salts thereof. The compounds possess a potent nitric oxide synthase inhibiting activity and are useful as therapeutics of cerebrovascular diseases.